Hochschulschrift
Mechanistic understanding of enhanced human oral bioavailability of fenofibric acid from novel lipid carriers using semi-physiologically based pharmacokinetic model and various analytical approaches including biorelevant dissolution testing
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISBN
-
9783736997684
373699768X
- Maße
-
21 cm
- Umfang
-
XXI, 196 Seiten
- Ausgabe
-
1. Auflage
- Sprache
-
Englisch
- Anmerkungen
-
Illustrationen, Diagramme
Johann Wolfgang Goethe University in Frankfurt am Main, Dissertation, 2018
- Klassifikation
-
Medizin, Gesundheit
Chemie
- Ereignis
-
Veröffentlichung
- (wo)
-
Göttingen
- (wer)
-
Cuvillier Verlag
- (wann)
-
2018
- Urheber
- Beteiligte Personen und Organisationen
- Inhaltsverzeichnis
- Rechteinformation
-
Bei diesem Objekt liegt nur das Inhaltsverzeichnis digital vor. Der Zugriff darauf ist unbeschränkt möglich.
- Letzte Aktualisierung
-
11.06.2025, 14:10 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Hochschulschrift
Beteiligte
- Fei, Yang
- Eric Cuvillier. Firma
- Cuvillier Verlag
Entstanden
- 2018
Ähnliche Objekte (12)
Physiologically based dissolution tests : experiences with poorly soluble drugs
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. Case example: Naproxen
Pharmacokinetic and bioavailability investigations of the neurotropic musculotropic spasmolytic agent denaverine
Optimisation of molecular radiotherapy for leukaemia patients using physiologically based pharmacokinetic models
Important pharmacokinetic parameters for individualization of 177Lu‐PSMA therapy: a global sensitivity analysis for a physiologically‐based pharmacokinetic model
Application of population, physiologically based, and semi-physiological pharmacokinetic modeling to assess sources of pharmacokinetic variability in individual drugs
Physiologically based pharmacokinetic (PBPK) modeling for dynamical liver function tests and CYP phenotyping
Physiologically based pharmacokinetic modelling in health and disease for the support of pharmacotherapy
Development and evaluation of a physiologically based pharmacokinetic model for populations of pregnant women
Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development and Research: Methodology, Applications, and Limitations
Physiologically based dissolution tests : experiences with poorly soluble drugs
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. Case example: Naproxen
Pharmacokinetic and bioavailability investigations of the neurotropic musculotropic spasmolytic agent denaverine
Optimisation of molecular radiotherapy for leukaemia patients using physiologically based pharmacokinetic models
Important pharmacokinetic parameters for individualization of 177Lu‐PSMA therapy: a global sensitivity analysis for a physiologically‐based pharmacokinetic model
Application of population, physiologically based, and semi-physiological pharmacokinetic modeling to assess sources of pharmacokinetic variability in individual drugs
Physiologically based pharmacokinetic (PBPK) modeling for dynamical liver function tests and CYP phenotyping
Physiologically based pharmacokinetic modelling in health and disease for the support of pharmacotherapy
Development and evaluation of a physiologically based pharmacokinetic model for populations of pregnant women
Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development and Research: Methodology, Applications, and Limitations
Physiologically based dissolution tests : experiences with poorly soluble drugs
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. Case example: Naproxen
Pharmacokinetic and bioavailability investigations of the neurotropic musculotropic spasmolytic agent denaverine
Optimisation of molecular radiotherapy for leukaemia patients using physiologically based pharmacokinetic models
Important pharmacokinetic parameters for individualization of 177Lu‐PSMA therapy: a global sensitivity analysis for a physiologically‐based pharmacokinetic model
Application of population, physiologically based, and semi-physiological pharmacokinetic modeling to assess sources of pharmacokinetic variability in individual drugs
Physiologically based pharmacokinetic (PBPK) modeling for dynamical liver function tests and CYP phenotyping
Physiologically based pharmacokinetic modelling in health and disease for the support of pharmacotherapy
Development and evaluation of a physiologically based pharmacokinetic model for populations of pregnant women